📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
37 announcements match the current filters (relevance ≥ 5).
Rainbow Children's Medicare Re-appoints CMD, Recommends ₹3.5 Dividend
Rainbow Children's Medicare has recommended a final dividend of ₹3.5 per share for FY26, with the record date set for July 21, 2026. The board has approved the re-appointment of founding promoter Dr. Ramesh Kancharla as CMD and Dr. Dinesh Kumar Chirla as Whole Time Director for five-year terms starting August 2026. Additionally, two independent directors have been re-appointed for a second five-year term, ensuring leadership continuity for the next half-decade. The company also confirmed the re-appointment of M/s. Lavanya & Associates LLP as cost auditors for the upcoming financial year.
Key Highlights
Recommended a final dividend of ₹3.5 per equity share (@35%) for the financial year ended March 31, 2026.
Re-appointed Dr. Ramesh Kancharla as Chairman and Managing Director for a 5-year term until August 2031.
Re-appointed Dr. Dinesh Kumar Chirla as Whole Time Director for a 5-year term until August 2031.
Fixed July 21, 2026, as the record date for dividend payment and the 28th Annual General Meeting.
Approved re-appointment of two Independent Directors and the Cost Auditors for FY 2026-27.
👀 What to Watch
Investors should view the leadership continuity and dividend declaration as signs of stability and confidence in long-term growth. Monitor the detailed FY26 financial results to assess the company's operational efficiency and margin trends.
Rainbow Children's Re-appoints Top Leadership and Declares ₹3.5 Dividend
Rainbow Children's Medicare has announced the re-appointment of its core leadership team, including CMD Dr. Ramesh Kancharla and WTD Dr. Dinesh Kumar Chirla, for five-year terms starting August 2026. The board also recommended a final dividend of ₹3.5 per equity share for FY26, representing a 35% payout on face value. Additionally, two independent directors, including Ms. Sundari R. Pisupati, were re-appointed for second five-year terms to ensure governance stability. These moves signal strong management continuity for the specialized pediatric healthcare provider through 2031.
Key Highlights
Recommended a final dividend of ₹3.5 per equity share (35% of face value) for FY2025-26
Re-appointed Dr. Ramesh Kancharla as CMD for a 5-year term from August 11, 2026, to August 10, 2031
Re-appointed Dr. Dinesh Kumar Chirla as Whole Time Director for a 5-year term starting August 2026
Fixed July 21, 2026, as the Record Date for dividend eligibility and the 28th AGM
Re-appointed Independent Directors Santanu Mukherjee and Sundari R. Pisupati for second 5-year terms
👀 What to Watch
Investors should take confidence in the management continuity and the company's commitment to shareholder returns via dividends. Monitor the upcoming AGM on July 29, 2026, for further strategic updates.
Rainbow Children's Medicare Approves ₹3.5 Dividend and Re-appoints Key Management
Rainbow Children's Medicare has announced its audited financial results for FY26 along with a final dividend of ₹3.5 per share, representing 35% of the face value. The board has approved the re-appointment of Dr. Ramesh Kancharla as Chairman and Managing Director for a five-year term starting August 2026. Additionally, several key board members, including Dr. Dinesh Kumar Chirla and two independent directors, have been re-appointed for five-year terms to ensure leadership continuity. The record date for the dividend and the 28th Annual General Meeting is set for July 21, 2026.
Key Highlights
Recommended a final dividend of ₹3.5 per equity share (35% on FV of ₹10) for FY 2025-26
Re-appointed Dr. Ramesh Kancharla as CMD for a 5-year term from August 11, 2026, to August 10, 2031
Fixed July 21, 2026, as the record date for dividend payment and the 28th AGM
Re-appointed Dr. Dinesh Kumar Chirla as Whole Time Director for a 5-year term
Approved re-appointment of Independent Directors Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati for second 5-year terms
👀 What to Watch
Investors should note the dividend record date of July 21, 2026, to ensure eligibility for the ₹3.5 payout. The continuity in top leadership is a positive signal for long-term stability and execution of the company's expansion plans.
Rainbow Children's Medicare Re-appoints Top Management; Recommends ₹3.5 Dividend
Rainbow Children's Medicare has approved the re-appointment of its core leadership, including CMD Dr. Ramesh Kancharla and WTD Dr. Dinesh Kumar Chirla, for five-year terms starting August 2026. The board also recommended a final dividend of ₹3.5 per equity share (35% of face value) for FY26, with a record date set for July 21, 2026. These leadership extensions ensure management continuity for the specialized pediatric healthcare provider through 2031. Additionally, the company confirmed audited financial results for FY26 with an unmodified auditor's opinion.
Key Highlights
Re-appointment of Dr. Ramesh Kancharla as CMD for a 5-year term until August 2031
Re-appointment of Dr. Dinesh Kumar Chirla as Whole Time Director for a 5-year term
Recommended a final dividend of ₹3.5 per share on a face value of ₹10
Record date for dividend eligibility and AGM fixed as July 21, 2026
Re-appointment of two Independent Directors for second 5-year terms to ensure board stability
👀 What to Watch
Investors should welcome the management continuity as it ensures the execution of long-term growth strategies. Those seeking the ₹3.5 dividend should ensure they hold shares before the July 21 record date.
Rainbow Children's Medicare Re-appoints CMD; Recommends ₹3.5 Final Dividend for FY26
Rainbow Children's Medicare has recommended a final dividend of ₹3.5 per share for FY26, with the record date fixed for July 21, 2026. The Board approved the re-appointment of founding promoter Dr. Ramesh Kancharla as Chairman & Managing Director for a five-year term starting August 11, 2026. Leadership continuity is further strengthened by the re-appointment of Dr. Dinesh Kumar Chirla as Whole Time Director and two independent directors for five-year terms. The company also confirmed audited financial results for FY26 with an unmodified auditor's opinion.
Key Highlights
Recommended a final dividend of ₹3.5 per equity share (35% of face value) for the financial year ended March 31, 2026.
Re-appointed Dr. Ramesh Kancharla as CMD for a five-year term from August 11, 2026, to August 10, 2031.
Fixed July 21, 2026, as the record date for dividend eligibility and the 28th Annual General Meeting.
Re-appointed Dr. Dinesh Kumar Chirla as Whole Time Director for a five-year term starting August 2026.
Statutory auditors S.R. Batliboi & Associates LLP issued an unmodified opinion on the FY26 audited financial results.
👀 What to Watch
Investors should benefit from the dividend payout and the stability offered by the long-term re-appointment of the core management team. Review the detailed FY26 financial results to assess the company's operational growth and expansion progress.
Rainbow Children's Medicare FY26: Network Grows to 24 Hospitals with 2,435 Bed Capacity
Rainbow Children's Medicare Limited (RCML) reported strong operational growth for FY26, expanding its network to 24 hospitals and 1,050+ doctors. The company recorded over 1.59 million outpatient visits and 104,000 inpatient admissions, supported by a total capacity of 2,435 beds. Key growth drivers included the acquisition of hospitals in Warangal and Guwahati, plus new facilities in Bengaluru. The hub-and-spoke model remains central to their strategy, optimizing tertiary and quaternary pediatric care delivery.
Key Highlights
Network expanded to 24 hospitals across 9 cities with a total capacity of 2,435 beds.
Achieved 1.59 million+ outpatient visits and 104,000+ inpatient admissions in FY26.
Facilitated 19,000+ deliveries, reinforcing leadership in integrated perinatal and pediatric care.
Executed strategic acquisitions of Prashanthi Hospital (Warangal) and Pratiksha Hospital (Guwahati).
Strong clinical foundation with 1,050+ full-time doctors and 3 JCI-accredited facilities.
👀 What to Watch
Investors should maintain a positive outlook as the company successfully integrates new acquisitions and scales its hub-and-spoke model. Monitor the operational ramp-up of new hospitals in Bengaluru and Guwahati for future revenue growth.
Rainbow Children's Q4 PAT Surges 38.3% YoY to ₹782 Mn; Declares ₹3.5 Dividend
Rainbow Children's Medicare reported a strong Q4 FY26 with revenue growing 24.3% YoY to ₹4,599 Mn and PAT increasing by 38.3% to ₹782 Mn. The company successfully expanded its bed capacity by 23% YoY to 2,375 beds, while maintaining a healthy ARPOB of ₹62,464. Management indicated that the current phase of major capacity addition is complete, shifting focus to occupancy ramp-up and operational efficiency. A final dividend of ₹3.5 per share was recommended, supported by a robust cash position of ₹5,942 Mn.
Key Highlights
Q4 Revenue grew 24.3% YoY to ₹4,599 Mn, while PAT jumped 38.3% to ₹782 Mn.
EBITDA margins improved by 47 bps YoY to 31.5% in Q4 FY26.
Operational beds increased 19% YoY to 1,806, though occupancy slightly dipped to 45.3% due to new capacity.
ARPOB (Average Revenue Per Occupied Bed) saw a healthy 8% YoY growth to ₹62,464.
Board recommended a final dividend of ₹3.5 per equity share (35% of face value).
👀 What to Watch
Investors should monitor the occupancy ramp-up in the newly added Bengaluru and regional facilities as the company shifts from expansion to execution. The strong cash reserves of ₹5,942 Mn and internal accruals provide a solid foundation for completing planned projects in Gurugram and Pune without external debt.
Rainbow Children's Medicare Recommends ₹3.5 Dividend; Sets July 21 as Record Date
Rainbow Children's Medicare has recommended a final dividend of ₹3.5 per equity share (35% of face value) for the financial year ended March 31, 2026. The company has fixed July 21, 2026, as the record date to determine eligibility for the dividend and the upcoming 28th Annual General Meeting. In a move to ensure leadership continuity, the Board also approved the re-appointment of Dr. Ramesh Kancharla as Chairman and Managing Director for a five-year term. The financial results for FY26 were approved with an unmodified audit opinion from S.R. Batliboi & Associates LLP.
Key Highlights
Recommended a final dividend of ₹3.5 per equity share on a face value of ₹10 for FY2025-26
Fixed Tuesday, July 21, 2026, as the Record Date for dividend payment and AGM eligibility
Re-appointed Dr. Ramesh Kancharla as Chairman and Managing Director for 5 years until August 2031
Scheduled the 28th Annual General Meeting for Wednesday, July 29, 2026
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026
👀 What to Watch
Investors seeking the ₹3.5 dividend should ensure they hold the stock before the July 21 record date. The five-year extension for the founding leadership is a positive sign for long-term strategic stability.
Rainbow Children's Medicare Recommends ₹3.5 Dividend and Re-appoints Key Management
Rainbow Children's Medicare has recommended a final dividend of ₹3.5 per equity share for the financial year ended March 31, 2026. The board also approved the audited financial results for FY26 with an unmodified audit opinion, signaling financial transparency. Leadership stability is a key takeaway as the board approved the re-appointment of Dr. Ramesh Kancharla as Chairman and MD for a further five-year term. The company has scheduled its 28th AGM for July 29, 2026, and set the dividend record date for July 21, 2026.
Key Highlights
Recommended a final dividend of ₹3.5 per equity share (35% of face value) for FY 2025-26.
Fixed July 21, 2026, as the record date for dividend payment and AGM attendance.
Re-appointed Dr. Ramesh Kancharla as Chairman and Managing Director for a 5-year term until 2031.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Re-appointed Dr. Dinesh Kumar Chirla as Whole Time Director for a 5-year term.
👀 What to Watch
Investors seeking dividend income should ensure they hold shares before the July 21, 2026 record date. The long-term re-appointment of the core management team is a positive sign for strategic continuity.
Rainbow Children's Medicare Recommends ₹3.5 Dividend and Re-appoints Top Management
Rainbow Children's Medicare has approved its audited financial results for the fiscal year ended March 31, 2026, receiving a clean audit opinion from S.R. Batliboi & Associates. The board recommended a final dividend of ₹3.5 per equity share, representing 35% of the face value. Significant management continuity was established with the re-appointment of the Chairman and Managing Director, along with other key directors, for five-year terms. The record date for the dividend is set for July 21, 2026, with the Annual General Meeting scheduled for July 29, 2026.
Key Highlights
Recommended a final dividend of ₹3.5 per equity share (35% of face value) for FY 2025-26.
Re-appointed Dr. Ramesh Kancharla as Chairman and Managing Director for a five-year term until 2031.
Fixed July 21, 2026, as the record date for dividend payment and AGM attendance.
Statutory auditors issued an unmodified opinion on both standalone and consolidated financial results.
Re-appointed Dr. Dinesh Kumar Chirla as Whole Time Director for a five-year term starting August 2026.
👀 What to Watch
Investors should ensure they hold shares by the record date of July 21, 2026, to qualify for the ₹3.5 dividend. The long-term re-appointment of the founding management team provides positive visibility on leadership stability.
Rainbow Children's Medicare GST Appeal Disallowed; Company to Pursue Higher Authority
Rainbow Children's Medicare Limited reported that its appeal against a GST demand notice issued in May 2024 has been disallowed by the Principal Commissioner of Customs and Central Tax (Appeals-1). The company received the order on May 7, 2026, which upholds the previous demand under Section 74(5) of the CGST Act. Management intends to file a further appeal with the appropriate higher authority and states that no payments or penalties have been made yet. While there is no immediate material impact on operations, the final financial outcome remains subject to further adjudication.
Key Highlights
Appeal against the May 29, 2024, GST demand notice was disallowed and the original order upheld.
Order from the Principal Commissioner of Customs and Central Tax (Appeals-1) was received on May 7, 2026.
The company is in the process of filing a further appeal before the appropriate higher authority based on expert advice.
No compensation, penalty, or payment has been made by the company as of the disclosure date.
Management maintains there is no immediate material impact on the financial position or operations at this stage.
👀 What to Watch
Investors should monitor future disclosures to identify the specific monetary value of the GST demand to quantify potential liability. The decision to appeal further suggests the company believes it has a strong case, but the litigation remains an ongoing regulatory risk.
Rainbow Children's Expands Bengaluru Network with New 60-Bed Hospital and IVF Centre
Rainbow Children's Medicare has inaugurated a new 60-bed spoke hospital in HRBR Layout and a dedicated IVF centre in Mahadevapura, Bengaluru. The total project cost for these facilities is approximately ₹52 crore, which has been funded entirely through internal accruals. This expansion increases the company's total bed capacity to approximately 2,435 beds across India. The move strengthens the company's hub-and-spoke model in the high-growth Bengaluru market, specifically targeting young urban populations near major IT hubs.
Key Highlights
Inaugurated a 60-bed spoke hospital in HRBR Layout and a dedicated IVF centre in Mahadevapura, Bengaluru.
Total investment of ₹52 crore (₹42 Cr for the hospital and ₹10 Cr for the IVF centre) funded via internal accruals.
Total group bed capacity increased from 2,375 to approximately 2,435 beds.
Strategic placement near Manyata Tech Park and major IT corridors to capture high-demand urban demographics.
Company occupancy stood at ~46.6% as of 9M FY2025-26, indicating significant headroom for growth.
👀 What to Watch
Investors should view this as a positive strategic expansion that leverages the company's successful hub-and-spoke model in a key growth market. Monitor the occupancy ramp-up in these new facilities over the coming quarters to evaluate the return on the ₹52 crore investment.
Rainbow Children's Medicare Q3 FY26: Revenue Up 12% to ₹445 Cr; New CEO Appointed
Rainbow Children's Medicare reported a 12% YoY revenue growth to ₹445.4 crores for Q3 FY26, while PAT grew 7% to ₹73.9 crores. The company is transitioning from a heavy expansion phase to an execution phase, having recently commissioned hospitals in Rajahmundry and Electronic City. Despite steady operational growth in deliveries (up 16%) and IP discharges (up 9%), occupancy remained at 47.2% due to muted seasonal illnesses. The appointment of Abrarali Dalal as CEO and a strong cash reserve of ₹579 crores position the company for future organic and inorganic growth.
Key Highlights
Revenue grew 12% YoY to ₹445.4 crores; EBITDA increased 9% to ₹147 crores with a 33% margin.
Deliveries saw an impressive 16% YoY growth, while IP discharges and OP volumes rose by 9% and 18% respectively.
Maintains a robust balance sheet with ₹579 crores in cash to fund future CAPEX and M&A through internal accruals.
Commissioned 100-bed Rajahmundry and 90-bed Electronic City units; 60-bed Hennur unit awaiting final approvals.
Successful first pediatric liver transplant in Bengaluru hub, achieving a 94% survival rate across the network.
👀 What to Watch
Investors should monitor the ramp-up of new units and the impact of the new CEO on improving occupancy levels, which currently sit below 50%. The stock remains a solid long-term play on specialized pediatric healthcare given the strong cash position and execution focus.
Rainbow Children's Medicare Q3 FY26 Revenue Up 21% YoY; OP Consultations Surge 18%
Rainbow Children's Medicare reported a robust 21.2% YoY growth in operating revenue for Q3 FY26, reaching ₹4,057 million. The company witnessed strong volume growth with out-patient consultations increasing by 18% and in-patient discharges by 9%. Expansion remains a key theme, with three new hospitals operationalized in Warangal, Guwahati, and Rajahmundry during the fiscal year. While EBITDA grew 14.3% to ₹1,313 million, overall occupancy moderated to 47.2% due to the significant addition of new capacity beds.
Key Highlights
Operating Revenue increased 21.2% YoY to ₹4,057 million in Q3 FY26.
EBITDA stood at ₹1,313 million, up 14.3% YoY, with a margin of 32.4%.
Out-patient consultations grew 18% YoY to 4,17,342; In-patient discharges rose 9% to 27,977.
ARPOB (Average Revenue Per Occupied Bed) improved by 9% YoY to ₹58,362.
Total capacity beds reached 2,285 following the addition of hospitals in Warangal, Guwahati, and Rajahmundry.
👀 What to Watch
Investors should monitor the occupancy levels and margin stabilization as the newly added hospitals move through their gestation periods. The strong growth in OP consultations and ARPOB suggests healthy underlying demand for specialized pediatric services.
Rainbow Children’s Q3 Revenue Up 11.9% YoY to ₹445 Cr; Focus Shifts to Execution
Rainbow Children’s Medicare reported a steady Q3 FY26 with revenue growing 11.9% YoY to ₹4,454 Mn and PAT increasing 7.2% to ₹739 Mn. While operational capacity expanded by 18% to 2,285 beds, occupancy rates dipped to 47.19% from 53.20% YoY due to the rapid addition of new units in Rajahmundry and Bengaluru. The company has largely completed its current expansion cycle and is now focusing on operational excellence and ramping up occupancy in new facilities. A strong cash position of ₹5,792 Mn supports future growth and ongoing projects in Gurugram and Pune without external debt.
Key Highlights
Revenue grew 11.9% YoY to ₹4,454 Mn, while EBITDA margins remained healthy at 33.0%.
Operational beds increased by 15% to 1,758, though occupancy fell 601 bps to 47.19% due to new capacity additions.
ARPOB (Average Revenue Per Occupied Bed) improved by 9% YoY to ₹58,362.
Commissioned two new hospitals in Rajahmundry (100 beds) and Electronic City, Bengaluru (90 beds).
Maintains a robust cash and investment balance of ₹5,792 Mn as of December 31, 2025.
👀 What to Watch
Investors should monitor the occupancy ramp-up in newly commissioned units, as the shift from expansion to execution is expected to drive margin improvement. The company's ability to fund large-scale expansions in NCR and Pune through internal accruals remains a significant long-term positive.
Rainbow Children's Medicare Q3 Standalone PAT at ₹658.2 Mn, Revenue Up 3.4% YoY
Rainbow Children's Medicare reported a standalone revenue of ₹3,943.52 million for Q3 FY26, a 3.4% increase over ₹3,815.65 million in Q3 FY25. Standalone Profit After Tax (PAT) declined slightly by 1.7% YoY to ₹658.24 million, down from ₹669.75 million. Sequentially, the performance was lower than Q2 FY26, where revenue was ₹4,084.96 million and PAT was ₹731.67 million. The board also confirmed the appointment of Mr. Abrarali Dalal as CEO starting January 2026.
Key Highlights
Standalone Revenue from operations grew 3.35% YoY to ₹3,943.52 million
Standalone Profit After Tax (PAT) decreased by 1.7% YoY to ₹658.24 million
Total expenses rose to ₹3,166.74 million from ₹3,023.00 million in the previous year's quarter
Basic EPS for the quarter stood at ₹6.48 compared to ₹6.60 in Q3 FY25
Mr. Abrarali Dalal officially took charge as the Chief Executive Officer (CEO) on January 20, 2026
👀 What to Watch
The results indicate a period of consolidation with flat YoY profit growth and a sequential dip in margins. Investors should monitor the new CEO's impact on operational efficiency and the company's expansion strategy in the specialized pediatric healthcare market.
Rainbow Children's Medicare Launches 90-Bed Hospital in Bengaluru; Total Capacity at 2,375 Beds
Rainbow Children’s Medicare Limited (RCML) has inaugurated a new 90-bed spoke hospital in Electronic City, Bengaluru, increasing its total capacity to approximately 2,375 beds. The project, costing approximately ₹55 crore, was funded entirely through internal accruals, demonstrating strong cash flow management. This facility marks the company's fifth hospital in Bengaluru and will operate under the hub-and-spoke model linked to the Marathahalli hub. This expansion targets a high-growth corridor with a young population, enhancing the company's footprint in a key focus market.
Key Highlights
New 90-bed spoke hospital launched in Electronic City, Bengaluru, increasing total capacity to ~2,375 beds.
Total project investment of approximately ₹55 crore financed through internal accruals.
Strengthens the hub-and-spoke model in Bengaluru, serving as a spoke to the Marathahalli hub.
Company occupancy stood at 46.3% in Q2 FY 2025-26 prior to this addition.
The facility offers comprehensive pediatric and perinatal services, including neonatal and pediatric intensive care.
👀 What to Watch
The expansion is a positive indicator of the company's growth strategy and ability to scale using internal funds. Investors should monitor the occupancy ramp-up at the new facility to assess its impact on future earnings.
